Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tissue Regenix ( (GB:TRX) ) has provided an update.
Tissue Regenix Group PLC has announced the availability of its Annual Report and Accounts, along with the notice of its upcoming AGM, on its website. The AGM is scheduled for 23 July 2025, where shareholders can engage with the Board. Additionally, the company will host an online presentation of its final results on 1 July 2025, open to all existing and potential shareholders. This announcement underscores Tissue Regenix’s commitment to transparency and stakeholder engagement, potentially strengthening its position in the regenerative medical devices industry.
More about Tissue Regenix
Tissue Regenix is a leading medical device company specializing in regenerative medicine. It utilizes its patented decellularisation technology, dCELL®, to create acellular tissue scaffolds that are not rejected by the patient’s body, addressing clinical needs in sports medicine, foot and ankle injuries, and wound care. The company also acquired CellRight Technologies, which focuses on regenerative medicine for various surgical procedures.
Average Trading Volume: 36,388
Technical Sentiment Signal: Sell
Current Market Cap: £22.08M
For an in-depth examination of TRX stock, go to TipRanks’ Overview page.